ImmunityBio, Inc.
IBRX
ImmunityBio, Inc., a clinical-stage biotechnology company, develops therapies and vaccines to treat cancers and infectious diseases. It offers immunotherapy and cell therapy platforms, including antibody cytokine fusion proteins, synthetic immunomodulators, vaccine technologies, natural killer cells, and adaptive (T cell) immune systems. The company also develops therapeutic agents, which are in Pā¦ read more
Healthcare
Biotechnology
11 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$7.91
Price+2.46%
$0.19
1Y
Price
Market Cap
$8.285b
Mid
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.-432.4%
EBITDA Margin-449.6%
Net Profit Margin-287.2%
Free Cash Flow Margin-432.4%
EBITDA Margin-449.6%
Net Profit Margin-287.2%
Free Cash Flow MarginRevenue
$165.792m
+46.4%
1y CAGR+995.1%
3y CAGR+786.1%
5y CAGREarnings
-$992.357m
-182.4%
1y CAGR-46.1%
3y CAGR-44.6%
5y CAGREPS
-$0.97
-155.3%
1y CAGR-23.5%
3y CAGR-20.3%
5y CAGRBook Value
-$1.046b
$628.504m
Assets$1.674b
Liabilities$813.061m
DebtDebt to Assets
129.4%
-0.9x
Debt to EBITDAFree Cash Flow
-$365.626m
-18.4%
1y CAGR+1.3%
3y CAGR+2.1%
5y CAGRNo items found.
Press Releases
Statements and updates from the company